InnoCare Pharma has entered a research collaboration and license agreement with Eli Lilly and Company to use its drug discovery platform against up to five targets addressing critical unmet medical needs. InnoCare may receive up to $100 million in upfront and near-term payments, approximately $3.25 billion in development and commercial milestones, and single-digit tiered royalties on annual net sales of commercialized products. The companies have not disclosed the therapeutic areas or targets. The deal extends Lilly's active biotech dealmaking and adds to InnoCare's partnerships with Western pharmaceutical companies. Payments remain subject to conditions, and the final amount is uncertain.